With the potency, in vivo tolerability,pharmacokinetics, and TRPM4-dependence of ErSO-TFPy established,an evaluation was made in a cell culture of how ErSO-TFPy compares with other clinically used or emerging drugs for ERα+breast cancer. Here, TRPM4 is linked to breast carcinoma.